ClinicalTrials.gg
CompletedNCT02008318Updated Sep 11, 2019Results posted

A Study of Galunisertib in Participants With Myelodysplastic Syndromes

A Phase 2/3 interventional study of Galunisertib and Placebo in Myelodysplastic Syndromes, sponsored by Eli Lilly and Company. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 160 studies in Myelodysplastic Syndromes with a site in Germany — 16 open to participants now, 31 under way, 13 of them phase 3. Myelodysplastic Syndromes · Germany.

Enrollment
103rd of 143
43 · median 87
Started
2014
with 12 others
Phase 2/3
5 of 160
1 open now
Registered
68th of 160
by date

Among the 160 studies in Myelodysplastic Syndromes with a site in Germany, this one is the 103rd largest by enrollment of the 143 interventional ones that give a count, is one of 13 that started in 2014, is one of 5 in phase 2/3, and was the 68th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

16 of the 160 studies in Myelodysplastic Syndromes with a site in Germany are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Myelodysplastic Syndromes with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of the study drug known as galunisertib in participants with myelodysplastic syndromes (MDS). Participants with different degrees of disease (very low, low, and intermediate risk) will be studied. The study treatment is expected to last about 6 months for each participant.

03

Conditions studied

  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria
  • Participants with 5q deletions are allowed only if they have failed or are intolerant of lenalidomide treatment
  • Participants must have a Revised International Prognostic Scoring System (IPSS-R) category of very low-, low-, or intermediate-risk disease
  • In the 8 weeks prior to registration, participants in phase 2 should have anemia with ≤10.0 g/dL (based on the average of 2 baseline measurements and untransfused for at least 1 week) with or without red blood cell (RBC) transfusion dependence confirmed for a minimum of 8 weeks before enrollment
  • For phase 3, participants should have anemia with RBC transfusion dependence confirmed within 8 weeks before enrollment
  • Performance status ≤2 on the (ECOG) scale

Exclusion criteria

Exclusion Criteria:

  • No history of moderate or severe cardiac disease
  • No prior history of acute myeloid leukemia (AML)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Phase (ph) 2: Galunisertib + BSC

    Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.

    Drug: Galunisertib

  • Placebo comparator
    Ph 3: Placebo + BSC

    Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.

    Drug: Placebo

  • Experimental
    Ph 3: Galunisertib + BSC

    150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.

    Drug: Galunisertib

Interventions

  • Administered orally

    Also known as: LY2157299

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hematological Improvement (HI)

    Percentage of participants with hematological improvement (HI) based on International Working Group (IWG) 2006 criteria in participants with very low, low, and intermediate-risk myelodysplastic syndromes treated with Galunisertib plus best supportive care, as assessed by the International Prognostic Scoring System (IPSS-R). To be classified as an HI responder, the HI response must have lasted at least 8 weeks (56 days).

    Time frame: Baseline through end of study treatment (24 weeks)

  2. Percentage of Participants Who Are Transfusion-free or Have Hemoglobin (Hb) Increase ≥1.5 Grams/Deciliter Maintained for 8 Weeks During Phase 3

    Comparison of the percentage of participants with very low-, low-,and intermediate-risk MDS who were transfusion-free or had an increase ≥1.5 g/dL in hemoglobin (Hb) maintained for at least 8 weeks within the first 24 weeks of treatment with galunisertib plus best supportive care or placebo plus best supportive care and assessed by IPSS-R. The Phase 3 portion of this study was not conducted because efficacy level required in phase 2 to move forward to phase 3 was not achieved.

    Time frame: Baseline through end of study treatment (24 weeks)

Secondary outcomes

  1. Change From Baseline in Brief Fatigue Inventory (BFI)

    The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity of fatigue is assessed using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine.

    Time frame: Baseline, Follow up (final visit up to 24 months)

  2. Change From Baseline in EuroQol 5-Dimension 5 Level Instrument

    EuroQol 5-Dimension 5 Level Instrument (EQ-5D-5L) was not conducted, trial terminated prior to Phase 3. No data collected.

    Time frame: Phase 3: Baseline, Cycle 2, Cycle 4, Cycle 6 (Cycle = 28 days)

  3. Percentage of Participants With Cytogenetic Response

    Percentage of Participants with Cytogenetic Response with either complete or partial response. Complete cytogenetic response is the disappearance of the chromosomal abnormality without appearance of new ones. Partial cytogenetic response is at least 50% reduction of the chromosomal abnormality.

    Time frame: Baseline through end of study treatment (24 weeks)

  4. Percentage of Participants Who Are Hospitalized (Resource Utilization)

    Percentage of any participant with a hospitalization admission and discharge date on the same day are counted as a half-day in the duration of hospitalization.

    Time frame: Baseline through end of study treatment (24 weeks)

  5. Population Pharmacokinetics (PK): Mean Population Clearance of Galunisertib

    Population mean (between-participant coefficient variation \[CV%\]) apparent clearance.

    Time frame: Day 1 pre-dose & between 0.5 to 2 hours post dose; Day 14 pre-dose, between 0.5 to 2 & between 3 to 5 hours post dose; Days 15 & 16 (if logistically possible) between 0.5 to 2 hours post dose

  6. Overall Survival (OS)

    Overall survival is defined as the time from the date of first dose to the date of death from any cause.

    Time frame: Baseline to date of death from any cause (Up to 2 years)

  7. Number of Participants With a Change in Bone Marrow Fibrosis Grading

    Change from baseline in bone marrow fibrosis measured the number of participants with a change in bone marrow fibrosis grading (negative, mild, moderate, and severe).

    Time frame: Baseline, Cycle 6 (Cycle = 28 days)

07

Results

Posted Mar 7, 2019
Limitations and caveats
The response rate at interim analysis did not meet the predefined rate. The Phase 3 portion was not initiated and the sponsor decided on early discontinuation of the study at the conclusion of Phase 2.

Participant flow

Participant flow — Overall Study
MilestoneGalunisertib at 150 mgGalunisertib at 80 mg
Started412
Received at least 1 dose of study drug412
Completed291
Not completed121
Withdrew: Adverse event40
Withdrew: Physician decision20
Withdrew: Progressive disease20
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject30

Outcome measures

PrimaryPercentage of Participants With Hematological Improvement (HI)

Percentage of participants with hematological improvement (HI) based on International Working Group (IWG) 2006 criteria in participants with very low, low, and intermediate-risk myelodysplastic syndromes treated with Galunisertib plus best supportive care, as assessed by the International Prognostic Scoring System (IPSS-R). To be classified as an HI responder, the HI response must have lasted at least 8 weeks (56 days).

Time frame:
Baseline through end of study treatment (24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Hematological Improvement (HI)
percentage of participantsGalunisertib at 150 mgArm: Galunisertib at 80 mg
Percentage of Participants With Hematological Improvement (HI)31.7 (18.1 to 48.1)0.0 (0.0 to 84.2)
PrimaryPercentage of Participants Who Are Transfusion-free or Have Hemoglobin (Hb) Increase ≥1.5 Grams/Deciliter Maintained for 8 Weeks During Phase 3

Comparison of the percentage of participants with very low-, low-,and intermediate-risk MDS who were transfusion-free or had an increase ≥1.5 g/dL in hemoglobin (Hb) maintained for at least 8 weeks within the first 24 weeks of treatment with galunisertib plus best supportive care or placebo plus best supportive care and assessed by IPSS-R. The Phase 3 portion of this study was not conducted because efficacy level required in phase 2 to move forward to phase 3 was not achieved.

Time frame:
Baseline through end of study treatment (24 weeks)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Brief Fatigue Inventory (BFI)

The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity of fatigue is assessed using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine.

Time frame:
Baseline, Follow up (final visit up to 24 months)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Brief Fatigue Inventory (BFI)
units on a scaleGalunisertib at 150 mgGalunisertib at 80 mg
Current Fatigue at Follow-up0.818 ± 0.42-1.005 ± 2.08
Usual Fatigue at Follow-up-0.017 ± 0.37-0.157 ± 1.87
Worst Fatigue at Follow-up-0.191 ± 0.38-0.063 ± 1.93
SecondaryChange From Baseline in EuroQol 5-Dimension 5 Level Instrument

EuroQol 5-Dimension 5 Level Instrument (EQ-5D-5L) was not conducted, trial terminated prior to Phase 3. No data collected.

Time frame:
Phase 3: Baseline, Cycle 2, Cycle 4, Cycle 6 (Cycle = 28 days)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Cytogenetic Response

Percentage of Participants with Cytogenetic Response with either complete or partial response. Complete cytogenetic response is the disappearance of the chromosomal abnormality without appearance of new ones. Partial cytogenetic response is at least 50% reduction of the chromosomal abnormality.

Time frame:
Baseline through end of study treatment (24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Cytogenetic Response
percentage of participantsGalunisertib at 150 mgGalunisertib at 80 mg
Percentage of Participants With Cytogenetic Response2.4 (0.1 to 12.9)0 (0 to 0)
SecondaryPercentage of Participants Who Are Hospitalized (Resource Utilization)

Percentage of any participant with a hospitalization admission and discharge date on the same day are counted as a half-day in the duration of hospitalization.

Time frame:
Baseline through end of study treatment (24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Hospitalized (Resource Utilization)
percentage of participantsGalunisertib at 150 mgGalunisertib at 80 mg
Percentage of Participants Who Are Hospitalized (Resource Utilization)24.30
SecondaryPopulation Pharmacokinetics (PK): Mean Population Clearance of Galunisertib

Population mean (between-participant coefficient variation \[CV%\]) apparent clearance.

Time frame:
Day 1 pre-dose & between 0.5 to 2 hours post dose; Day 14 pre-dose, between 0.5 to 2 & between 3 to 5 hours post dose; Days 15 & 16 (if logistically possible) between 0.5 to 2 hours post dose
Reported as:
Geometric mean · Liter per hour (L/h)
Population Pharmacokinetics (PK): Mean Population Clearance of Galunisertib
Liter per hour (L/h)Galunisertib
Population Pharmacokinetics (PK): Mean Population Clearance of Galunisertib32 ± 52
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of first dose to the date of death from any cause.

Time frame:
Baseline to date of death from any cause (Up to 2 years)
Reported as:
Median · days
Overall Survival (OS)
daysGalunisertib at 150 mg
Overall Survival (OS)679 (29 to 729)
SecondaryNumber of Participants With a Change in Bone Marrow Fibrosis Grading

Change from baseline in bone marrow fibrosis measured the number of participants with a change in bone marrow fibrosis grading (negative, mild, moderate, and severe).

Time frame:
Baseline, Cycle 6 (Cycle = 28 days)
Reported as:
Number · participants
Number of Participants With a Change in Bone Marrow Fibrosis Grading
participantsGalunisertib at 150 mg
Number of Participants With a Change in Bone Marrow Fibrosis Grading11

Adverse events

Collected over Baseline through end of study treatment or death from any cause (Up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Galunisertib at 150 mg—8/41 (19.5%)33/41 (80.5%)
Galunisertib at 80 mg—0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventGalunisertib at 150 mgGalunisertib at 80 mg
Cardiac failureCardiac disorders2/410/2
Respiratory failureRespiratory, thoracic and mediastinal disorders2/410/2
Febrile neutropeniaBlood and lymphatic system disorders1/410/2
LymphadenopathyBlood and lymphatic system disorders1/410/2
Crohn's diseaseGastrointestinal disorders1/410/2
Retroperitoneal haemorrhageGastrointestinal disorders1/410/2
PneumoniaInfections and infestations1/410/2
Respiratory syncytial virus infectionInfections and infestations1/410/2
Tongue abscessInfections and infestations1/410/2
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGalunisertib at 150 mgGalunisertib at 80 mg
AstheniaGeneral disorders5/411/2
CoughRespiratory, thoracic and mediastinal disorders0/411/2
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/411/2
DiarrhoeaGastrointestinal disorders7/410/2
VomitingGastrointestinal disorders5/410/2
PyrexiaGeneral disorders5/410/2
FatigueGeneral disorders4/410/2
NasopharyngitisInfections and infestations4/410/2
AnaemiaBlood and lymphatic system disorders3/410/2
NauseaGastrointestinal disorders3/410/2

Baseline characteristics

All participants (including the Galunisertib at 80 mg exploratory arm) who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Galunisertib at 150 mgGalunisertib at 80 mgTotal
Mean70.49 ± 7.6562.50 ± 10.6170.12 ± 7.83
Sex: Female, Male
Sex: Female, Male(Participants)Galunisertib at 150 mgGalunisertib at 80 mgTotal
Female15116
Male26127
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Galunisertib at 150 mgGalunisertib at 80 mgTotal
Hispanic or Latino505
Not Hispanic or Latino32234
Unknown or Not Reported404
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Galunisertib at 150 mgGalunisertib at 80 mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White41243
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Galunisertib at 150 mgGalunisertib at 80 mgTotal
Italy808
Germany23023
Spain10212
IPSS-R Prognostic Risk Score
IPSS-R Prognostic Risk Score(Participants)Galunisertib at 150 mgGalunisertib at 80 mgTotal
Very Low= (≤1.5)202
Low= (>1.5 - 3)30131
Intermediate= (>3 - 4.5)9110
08

Study locations

14 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Düsseldorf, 40479, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jena, 07747, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lübeck, 23562, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulm, 89081, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Westerstede, 26655, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Firenze, 50134, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Novara, 28100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00161, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28050, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oviedo, 33011, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salamanca, 37007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46026, Spain
09

References and documents

Publications

  • Santini V, Valcarcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3. PubMed 31481511 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Mar 2016 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 3 years after primary completion. A results delay was requested in Aug 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 11, 2013
Start
Mar 2014
Primary completionActual
Mar 2016
CompletionActual
Sep 2017
Results delay requested
Aug 13, 2016
Results first posted
Mar 7, 2019
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02008318
Responsible party
Sponsor
First posted
Dec 11, 2013
Start date
Mar 2014
Primary completion
Mar 2016
Completion
Sep 2017
Results posted
Mar 7, 2019
Last update
Sep 11, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY-2157299

Start the discussion